Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3261-3268

  Fang, Nian ^a   Zhang, Hui Qing ^b   He, Bo ^b   Xie, Mei ^b   Lu, Shan ^b   Wan, Yi Ye ^b   Wang, Nong Rong ^a  

^a NANCHANG UNIVERSITY   (China)

^b JIANGXI CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Gastric cancer; Malignant ascites; Prognosis; Survival

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CISPLATIN; DIURETIC AGENT; TAXANE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; EASTERN COOPERATIVE ONCOLOGY GROUP SCORE; FEMALE; GASTRECTOMY; GROUPS BY AGE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT ASCITES; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARACENTESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITES; FEMALE; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84898820906     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1426-3     Document Type: Article

References (31)

1. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg. 1996;83(1):6-14. doi: 10.1002/bjs.1800830104.
2. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337-42. doi: 10.1056/NEJM199402033300508.
3. Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733-7. doi: 10.1001/archinte.161.22.2733.
4. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945-9. doi: 10.1093/annonc/mdl499.
5. Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23(8):1979-85. doi: 10.1093/annonc/mds178.
6. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589-97. doi: 10.1016/j.ejca.2005.11.018.
7. Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1-9. doi: 10.1007/ s10147 -012-0396-6.
8. Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer. 2011;14(1):81-90.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
10. Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35(7):386-90. doi: 10.1093/jjco/hyi109.
11. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22(3):237-9. doi: 10.1016/S0748-7983(96)80009-6.
12. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol. 1996;6(2):474-80.
13. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1-27. doi: 10.1007/s10120-012- 0163-4.
14. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67-70. doi: 10.1093/annonc/mdp260.
15. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18(5):886-91. doi: 10.1093/annonc/mdl501.
16. Mansour-Ghanaei F, Shafaghi A, Bagherzadeh AH, Fallah MS. Low gradient ascites: a seven-year course review. World J Gastroenterol. 2005;11(15):2337-9.
17. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer. 1990;62(3):440-3. doi: 10.1038/bjc.1990.314.
18. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656-62. doi: 10.1093/annonc/mds104.
19. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15(2):154-61. doi: 10.1007/s10120-011-0091- 8.
20. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-Franco H. Clinicopathologic characteristics of gastric cancer in a young patient population. J Gastrointest Surg. 2004;8(3):240-4. doi: 10.1016/j.gassur.2003.12. 009.
21. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, et al. Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol. 2008;15(5):1464-9. doi: 10.1245/s10434-008- 9809-1.
22. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Clinicopathological features of gastric carcinoma in younger and middle-aged patients: a comparative study. J Gastrointest Surg. 2006;10(7):1023-32. doi: 10.1016/j.gassur. 2006. 03.001.
23. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007;94(6):737-42. doi: 10.1002/bjs.5600.
24. Warren JR, Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1983;1(8336):1273-5.
25. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013;132(6):1272-6. doi: 10.1002/ijc.27965.
26. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392-7. doi: 10.1016/S0140-6736(08)61159-9.
27. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7(3):211-22. doi: 10.1016/S1470-2045(06)70586-1.
28. Qiu HB, Zhang LY, Keshari RP, Wang GQ, Zhou ZW, Xu DZ, et al. Relationship between H. pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer. 2010;10:374. doi: 10.1186/1471-2407-10- 374.
29. Chen HY, Zhu BH, Zhang CH, Yang DJ, Peng JJ, Chen JH, et al. High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci. 2012;103(1):73-9. doi: 10.1111/j.1349-7006.2011.02129.x.
30. Tamegai H, Kaiga T, Kochi M, Fujii M, Kanamori N, Mihara Y, et al. Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites. Cancer Chemother Pharmacol. 2013;71(3):727-31. doi: 10.1007/s00280-012-2066-9.
31. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209-21. doi: 10.1002/ijc.25423.